# OnCo record nct03394365 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03394365/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03394365", "NCT03394365" ;
  schema:name "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu"@en ;
  schema:alternateName "ALLELE"@en ;
  schema:description "A phase 3 trial of Tabelecleucel run by Pierre Fabre Medicament, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03394365/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03394365> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2017-12-29" ;
  onco:cancers <https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/> ;
  onco:technologies <https://onco.cc/technologies/virus-specific-t-cells/> ;
  onco:drugs <https://onco.cc/drugs/tabelecleucel/> ;
  onco:companies <https://onco.cc/companies/pierre-fabre/> .